Literature DB >> 11067942

Mechanisms of persistent NF-kappa B activity in the bronchi of an animal model of asthma.

F Bureau1, S Delhalle, G Bonizzi, L Fiévez, S Dogné, N Kirschvink, A Vanderplasschen, M P Merville, V Bours, P Lekeux.   

Abstract

In most cells trans-activating NF-kappaB induces many inflammatory proteins as well as its own inhibitor, IkappaB-alpha, thus assuring a transient response upon stimulation. However, NF-kappaB-dependent inflammatory gene expression is persistent in asthmatic bronchi, even after allergen eviction. In the present report we used bronchial brushing samples (BBSs) from heaves-affected horses (a spontaneous model of asthma) to elucidate the mechanisms by which NF-kappaB activity is maintained in asthmatic airways. NF-kappaB activity was high in granulocytic and nongranulocytic BBS cells. However, NF-kappaB activity highly correlated to granulocyte percentage and was only abrogated after granulocytic death in cultured BBSs. Before granulocytic death, NF-kappaB activity was suppressed by simultaneous addition of neutralizing anti-IL-1beta and anti-TNF-alpha Abs to the medium of cultured BBSs. Surprisingly, IkappaB-beta, whose expression is not regulated by NF-kappaB, unlike IkappaB-alpha, was the most prominent NF-kappaB inhibitor found in BBSs. The amounts of IkappaB-beta were low in BBSs obtained from diseased horses, but drastically increased after addition of the neutralizing anti-IL-1beta and anti-TNF-alpha Abs. These results indicate that sustained NF-kappaB activation in asthmatic bronchi is driven by granulocytes and is mediated by IL-1beta and TNF-alpha. Moreover, an imbalance between high levels of IL-1beta- and TNF-alpha-mediated IkappaB-beta degradation and low levels of IkappaB-beta synthesis is likely to be the mechanism preventing NF-kappaB deactivation in asthmatic airways before granulocytic death.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11067942     DOI: 10.4049/jimmunol.165.10.5822

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Persistent nuclear factor-kappa B activation in Ucp2-/- mice leads to enhanced nitric oxide and inflammatory cytokine production.

Authors:  Yushi Bai; Hiroki Onuma; Xu Bai; Alexander V Medvedev; Mary Misukonis; J Brice Weinberg; Wenhong Cao; Jacques Robidoux; Lisa M Floering; Kiefer W Daniel; Sheila Collins
Journal:  J Biol Chem       Date:  2005-03-09       Impact factor: 5.157

Review 2.  The interleukin-1 signalling pathway in astrocytes: a key contributor to inflammation in the brain.

Authors:  Paul N Moynagh
Journal:  J Anat       Date:  2005-09       Impact factor: 2.610

3.  Effects of Angelicin on Ovalbumin (OVA)-Induced Airway Inflammation in a Mouse Model of Asthma.

Authors:  Da-Zhen Wei; Xian-Yang Guo; Li-Na Lin; Meng-Xiang Lin; Yu-Qiang Gong; Bin-Yu Ying; Ming-Yuan Huang
Journal:  Inflammation       Date:  2016-12       Impact factor: 4.092

4.  Nuclear factor kappa B induction in airway epithelium increases lung inflammation in allergen-challenged mice.

Authors:  James R Sheller; Vasiliy V Polosukhin; Daphne Mitchell; D-S Cheng; R Stokes Peebles; Timothy S Blackwell
Journal:  Exp Lung Res       Date:  2009-12       Impact factor: 2.459

Review 5.  Use of cell permeable NBD peptides for suppression of inflammation.

Authors:  I Strickland; S Ghosh
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

6.  Reaginic antibodies from horses with recurrent airway obstruction produce mast cell stimulation.

Authors:  G Moran; H Folch; C Henriquez; A Ortloff; M Barria
Journal:  Vet Res Commun       Date:  2012-08-12       Impact factor: 2.459

Review 7.  Type I IL-1 receptor (IL-1RI) as potential new therapeutic target for bronchial asthma.

Authors:  Jyh-Hong Lee; Li-Chieh Wang; Hsin-Hui Yu; Yu-Tsan Lin; Yao-Hsu Yang; Bor-Luen Chiang
Journal:  Mediators Inflamm       Date:  2010-07-05       Impact factor: 4.711

Review 8.  Transcriptional regulation of cytokine function in airway smooth muscle cells.

Authors:  Deborah Clarke; Gautam Damera; Maria B Sukkar; Omar Tliba
Journal:  Pulm Pharmacol Ther       Date:  2009-04-22       Impact factor: 3.410

Review 9.  Nuclear factor-kappaB: its role in health and disease.

Authors:  Ashok Kumar; Yasunari Takada; Aladin M Boriek; Bharat B Aggarwal
Journal:  J Mol Med (Berl)       Date:  2004-06-03       Impact factor: 4.599

10.  Nuclear factor kappa B activation in human cord blood mononuclear cells.

Authors:  Christian H Schroeter; Bianca Schaub; Diane R Gold; Paola J Contreras; Oscar Manrique; Matthew W Gillman; Scott Weiss; Lyle J Palmer; David Perkins; Patricia W Finn
Journal:  Pediatr Res       Date:  2004-06-04       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.